In the context of parathyroid cancer, the prevalence of activating PI3K/AKT/mTOR pathway mutations in a substantial subset of patients provides a potential “actionable target” for therapeutic intervention, given that a number of PI3K pathway inhibitors have already been developed. The gene discussed is MTOR; the disease is malignant tumor of parathyroid gland.